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Phenotypic characterization of lung macrophages
in asthmatic patients: Overexpression of CCL17
Karl J. Staples, PhD,a Timothy S. C. Hinks, MB BS,a Jon A. Ward, BSc (Hons),a Victoria Gunn, BM,a
Caroline Smith, BA (Hons),b and Ratko Djukanovic, MDa,b Southampton, United KingdomBackground: Studies with monocyte-derived macrophages
(MDMs) and animal models have suggested a role for
alternatively activated (M2) macrophages in asthmatic
inflammation, but in vivo evidence for this phenotype in human
asthma is lacking.
Objective: To characterize the phenotype of lung macrophages
from asthmatic patients in relation to disease severity and
treatment.
Methods: M2 biomarkers were first identified by using MDMs
exposed to TH2 cytokines and then used to phenotype sputum and
bronchoalveolar lavage (BAL) macrophages from 12 healthy
control subjects, 12 patients with mild asthma, and 14 patients
with moderate asthma and to assess the effects of corticosteroids
and phosphatidylinositol 3-kinase (PI3K) inhibitors.
Results: Sputum macrophages from asthmatic patients
expressed significantly more CCL17 mRNA but less CD163 than
macrophages from healthy subjects. However, none of the other
M2 biomarkers were differentially expressed in asthmatic
patients, and ex vivo BAL cells spontaneously produced similar
amounts of M2 cytokines/chemokines (IL-10, CCL17, and
CCL22). CCL17 mRNA overexpression correlated weakly but
significantly with sputum eosinophilia (P 5 .0252) and was also
observed in macrophages from patients with moderate asthma
treated with inhaled steroids, suggesting relative insensitivity to
inhibition by corticosteroids. The PI3K inhibitor LY294002
inhibited basal CCL17 release from BAL cells and IL-4–
stimulated release from MDMs.
Conclusions: This study does not support the existence in
human asthma of the full M2 phenotype described to date but
points to upregulation of CCL17 in both patients with mild and
those with moderate asthma, providing a further source for this
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Asthma is a complex airways inflammatory disease involving
several cell types, with most research focusing on eosinophils and
CD41 TH2 cells,
1,2 the latter being an important source of the cy-
tokines IL-4, IL-5, and IL-13, which are key drivers of responses
to allergens.3 The role of macrophages in driving allergic airways
disease has been largely overlooked,4 even though they are the
most prevalent immune cell type in the lungs.
Macrophages have been broadly characterized as either clas-
sically activated (M1) or alternatively activated (M2) based on
phenotypes observed when macrophages are cultured in vitro in
the presence of LPS and IFN-g (M1) or IL-4 or IL-13 (M2).5
M2 macrophages generally express increased levels of receptors
involved in phagocytosis, such as CD206,6 CD163,7 and macro-
phage galactose C-type lectin (CLEC10A/CD301),8 as well as
important TH2 cell chemokines, including the CCR4 ligands
CCL17 and CCL22.5 Recent studies using animal models5,9 and
human monocytes10 have suggested a role for M2 macrophages
in allergic lung inflammation, but evidence of a similar phenotype
being relevant to human asthma has been lacking, and it is recog-
nized that there are differences between human and murine M2
expression profiles.11
Given that macrophages are the most numerous inflammatory
cell type in the airways, where TH2 cytokine levels are increased,
we postulated that lung macrophages from asthmatic patients are
of the M2 phenotype. We also hypothesized that macrophages
could be a major source of chemokines that attract CCR41 cells,
which we and others have shown as potentially playing a role in
asthma.12,13 Our previous work has demonstrated that CCR41 T
lymphocytes are a major source of TH2 cytokines
12 and that their
recruitment into the airways of asthmatic patients is controlled by
the CCR4 ligands CCL17 and CCL22. However, the source of
these chemokines has not been fully elucidated, with airway den-
dritic cells and epithelial cells being implicated to date.14-17
In the current study we first identified a panel ofM2 biomarkers
using monocyte-derived macrophages (MDMs) cultured in
M2-polarizing conditions; these biomarkers were then used to
phenotype sputum and bronchoalveolar lavage (BAL) macro-
phages from patients with mild steroid-naive asthma, patients
with moderate steroid-treated asthma, and nonatopic control
subjects. In addition to studying M1 (CD14 and TNF) and M2
(CCL17, CLEC10A, arginase 1 [ARG1], IL-10, IL-13, CD163,
CD206, and CLEC10A/CD301) biomarkers at the levels of
mRNA, intracellular protein, and cell-surface expression, we
also assessed the potential of airway macrophages recovered
from BAL fluid to produce a series of cytokines/chemokines
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reported as defining the M1 (TNF, IL-12, IL-6, and IL-8) and M2
(CCL17, CCL22, and IL-10) phenotypes.5 Having found that the
frequency of lung macrophages expressing CCL17 is increased in
both steroid-naive and steroid-treated asthmatic patients, we stud-
ied the effects of the corticosteroid fluticasone propionate and in-
hibitors of phosphatidylinositol 3-kinase (PI3K) on ex vivo
CCL17 production by MDMs and BAL fluid macrophages to ex-
plore their therapeutic potential.METHODS
Subjects
Twelve patients with mild atopic asthma taking short-acting b-agonists
alone, 14patientswithmoderate atopic asthma requiring inhaledcorticosteroids
for disease control (classified according to the Global Initiative for Asthma
criteria, www.ginasthma.org), and 12 healthy nonatopic control subjects were
studied (Table I). All subjects were nonsmokers with no respiratory tract infec-
tions for 6 weeks before the study. Atopy was assessed by using skin tests to
common aeroallergens. The studywas approved by the Southampton and South
West Hampshire Research Ethics Committee (reference 08/H0504/138).Benchmarking of M2 biomarkers by using
macrophages derived from blood monocytes
Initial experiments were conducted on MDMs derived from circulating
monocytes to establish a panel of biomarkers that reflect M2 macrophages for
subsequent phenotyping of lung macrophages from asthmatic and control
subjects. Monocytes were isolated to greater than 95% purity by means of
magnetic cell sorting and anti-CD14 antibodies and differentiated over
12 days in culture in RPMI-1640 (plus 10% FBS) into macrophages by using
2 ng/mLGM-CSF, a protocol shown to producemacrophages with phenotypic
and functional characteristics similar to those of lung macrophages.18,19 The
GM-CSF–containing media were then removed and replaced with media con-
taining 10 ng/mL recombinant human IL-4 or IL-13, and culture was contin-
ued for a further 24 hours. To check whether the differentiated cells displayed
an M2 phenotype, culture supernatants were analyzed by using ELISA for
CCL17 release, whereas the resuspended cells were analyzed for a panel of
M2 biomarkers (CD206, CD163, CLEC10A/CD301, Ccl17, and Arg1) by us-
ing a combination of flow cytometry and RT-PCR (see the Methods section in
this article’s Online Repository at www.jacionline.org).Sampling of lung macrophages
BAL and sputum induction were performed as previously described.20
Cells were isolated and immediately processed in fluorescence-activated
cell sorting (FACS) buffer containing 2 mg/mL human IgG for flow cytometry
and RT-PCR, and aliquots were collected for culture.Analysis of lung macrophage biomarkers
Flow cytometry. Phenotypic characterization of lung macrophages
was performedbymeans offlowcytometrywith a 9-color FACSAria cell sorter
and FACSDiva Software (version 5.0.3; BD Biosciences, Oxford, United
Kingdom). Cells were incubated in reagents from the Live/Dead Violet
Viability/Vitality kit (Invitrogen, Paisley, United Kingdom) and the
macrophage detection cocktail, consisting of anti-human CD45 phycoery-
thrin–Alexa Fluor 610 (PE-AF610; Invitrogen), anti-human CD3 phycoery-
thrin–cyanine 7 (PE-Cy7) and anti-humanHLA-DRallophycocyanin–cyanine
7 (APC-Cy7; all BD Biosciences). By using this protocol, CD451CD32HLA-
DR1 cells were greater than 90% pure macrophages, as shown by using cyto-
logic analysis of sorted cells (see Fig E1 in this article’s Online Repository at
www.jacionline.org).
Separate aliquots were additionally incubated in a cocktail of antibodies
specific for surface biomarkers (anti-CD206 allophycocyanin [APC] and
anti-CD14 peridinin chlorophyll protein–cyanine 5.5 [PerCP-Cy5.5] [both BD
Biosciences] or anti-CD301 Alexa Fluor 647 [AF647] and anti-CD163 PerCP-
Cy5.5 [both Cambridge Bioscience, Cambridge, United Kingdom]) or isotype
control antibodies. For intracellular staining, cell aliquots thathadbeen incubated
in themacrophage identification cocktailwere firstwashedwithFACSbuffer and
then incubated in Cytofix/Cytoperm (BD Biosciences). These were further
washed in 13 Perm/Wash and incubated with anti-human CD68–phycoerythrin
(PE), anti-human TNFAPC, anti–IL-10 AF647, or isotype control.
RT-PCR. RNA was extracted from FACS-sorted sputum and BAL
macrophages by using a Stratagene Microprep Kit (Stratagene, Amsterdam,
The Netherlands). Reverse transcription was carried out with a nanoScript
Reverse Transcriptase kit (PrimerDesign, Southampton, United Kingdom).
PCR amplifications for M2 biomarkers (CCL17, CLEC10A, and ARG1) were
performed on a Bio-Rad iCycler (Hemel Hempstead, United Kingdom) with
Precision 2X qPCR Mastermix and PerfectProbe primers (PrimerDesign; for
full sequences, see the Methods section in this article’s Online Repository).
Gene expression was normalized to b2-microglobulin gene expression and
quantified by using the DDCT method.
21Analysis of cytokine release by MDMs and BAL fluid
cells
MDMs from 5 subjects were cultured in RPMI-1640 (110% FBS) for
24 hours and stimulated with 10 ng/mL IL-4 in the presence or absence of a
range of concentrations of fluticasone propionate or PI3K inhibitors.
Similarly, BAL fluid cells (from 13 asthmatic patients) composed of a median
of 75%macrophages (for full differential cell counts, see the Methods section
in this article’s Online Repository) were cultured in AIM V medium (Invitro-
gen)without additional stimulants or in the presence of 10mMLY294002. The
mediumwas FBS free so as to avoid skewing of the macrophage phenotype by
factors in serum. After 24 hours, supernatants were retained for cytokine and
chemokine analysis.
Culture supernatants were analyzed by using a combination of ELISA
(R&D Systems, Abingdon, United Kingdom) and Luminex assay (Bio-Rad)
for IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-a, IFN-g,
CCL17, and CCL22 (for full details, see the Methods section in this article’s
Online Repository).Statistics
Statistical analyses were performed by using the Kruskal-Wallis or
Friedman ANOVA test with the Dunn Multiple Comparison test, the
Mann-Whitney U test, or the Wilcoxon signed-rank test, as appropriate
(GraphPad Prism version 3; GraphPad Software, San Diego, Calif). Results
were considered significant at a P value of less than .05.
TABLE I. Baseline characteristics of volunteer healthy control subjects, patients with mild asthma, and patients with moderate asthma
HC MA MO
No. 12 12 14
Sex (male/female) 5/7 6/6 6/8
Age (y) 23.5 (22-31) 24 (21-29.5) 44 (31.5-49)k
Atopy No Yes Yes
FEV1 (% predicted) 110.5 (102.3-120.3) 99.75 (88.6-109.7) 92.10 (80.35-105)
FEV1/FVC ratio 0.85 (0.79-0.88) 0.80 (0.72-0.83) 0.78 (0.70-0.85)
Methacholine PC20 Not achieved 2.59 (0.57-5.22) 1.14 (0.36-5.69)
Inhaled corticosteroids No No Yes
ACQ score ND 0.43 (0.15-0.71) 1.07 (0.43-1.57)
Sputum cells (%)
Macrophages 59.25 (46.78-73.15) 48.8 (33.5-61.9) 48.8 (42.9-76.05)
Neutrophils 34.9 (17.75-44) 34.15 (19.4-54.65) 36.0 (18.28-50.25)
Eosinophils 0.38 (0.0-0.98) 1.38 (0.75-5.5)* 2.5 (0.63-8.15)*
Lymphocytes 0.25 (0.0-0.50) 0.25 (0.0-0.75) 0.25 (0.0-0.5)
Epithelial cells 3.80 (0.75-8.30) 4.65 (1.0-7.75) 2.13 (1.0-9.25)
BAL fluid cells (%)
Macrophages 86.55 (74.9-90.15) 77.15 (74.55-84.65) 66.25 (52.75-80.75)*
Neutrophils 3.05 (1.63-5.25) 4.65 (2.38-5.15) 8.90 (5.4-16.05)§
Eosinophils 0.25 (0.0-0.88) 1.75 (1.0-3.38)* 2.40 (0.63-5.38)
Lymphocytes 1.0 (0.63-1.38) 1.13 (0.70-2.13) 1.0 (0.38-1.38)
Epithelial cells 9.30 (4.15-17.05) 12.15 (5.70-19.88) 17.15 (10.0-26.05)
Data are expressed as median values (interquartile ranges) to 2 decimal places. Data were analyzed by using the Kruskal-Wallis test followed by the Dunn multiple comparisons
test. PC20 and Asthma Control Questionnaire data were analyzed by using the Mann-Whitney U test.
ACQ, Asthma Control Questionnaire; FVC, forced vital capacity; HC, healthy control subjects; MA, patients with mild asthma; MO, patients with moderate asthma; ND, not
determined.
*P < .01 versus healthy control subjects.
P < .001 versus healthy control subjects.
P < .05 versus patients with mild asthma.
§P < .01 versus patients with mild asthma.
kP < .001 versus patients with mild asthma.
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Assessment of M2 biomarkers using MDMs
Both IL-4 and IL-13 significantly increased CCL17 and
CLEC10A gene expression (Fig 1, A, and see Fig E2 in this arti-
cle’s Online Repository at www.jacionline.org), with a trend to-
ward increased ARG1 gene expression (data not shown)
induced by IL-13. TH2 cytokine–treated MDMs (ie, M2
MDMs) also expressed significantly more HLA-DR and CD206
(Fig 1, B) and less CD14 and CD163 on their surface (Fig 1, B),
with no difference in CLEC10A (CD301) or CD36 expression
(data not shown). Small amounts of CCL17 were released from
unstimulated MDMs (80.36 39 pg/mL), and this was greatly in-
creased by IL-4 (390.3 6 204.9 pg/mL) and IL-13 (281.4 6
257.5 pg/mL). These experiments provided a panel of M2 bio-
markers previously reported by others.5,6,8,22M2 cell-surface marker expression on sputum and
BAL fluid macrophages
The M2 cell-surface biomarkers identified above were applied
to sputum and BAL macrophages from asthmatic patients and
control subjects and analyzed by using multichromatic flow
cytometry. The only surface biomarker that was differentially
expressed was CD163 (Fig 2 and Table II). Similar to
M2 MDMs, its expression was reduced in asthmatic patients
when compared with that seen in healthy subjects on macro-
phages in sputum (P 5 .0346, Kruskal-Wallis test) but not in
BAL fluid (P 5 .2893, Kruskal-Wallis test). Intracellular
TNF and IL-10 expression was also not different (Table II), al-
though BAL macrophages appeared to express more TNF thansputum macrophages. Intracellular IL-13 protein was not
detected.Gene expression analysis of lung macrophages
The 90% purity of macrophages obtained by using the above
method of selection was considered insufficient for gene
expression analysis because any small contamination with
other cell types could be amplified by means of PCR.
Therefore we added to the macrophage detection protocol the
Lineage (Lin) 1 antibody cocktail (BD Biosciences) to exclude
dendritic cells from the analysis. Cells sorted in this way
(CD451CD32Lin1HLA-DR1, Fig 3) from both sputum and
BAL fluid were, on average, 98% pure macrophages, as ascer-
tained by means of histochemical and morphologic analysis of
cytospin preparations. Up to 100,000 events were sorted into
RNA lysis buffer and stored at 2808C for RNA extraction
and RT-PCR.
Sputum macrophages from healthy control subjects expressed
little or no CCL17 mRNA (median value, 0; Fig 4), whereas sig-
nificantly greater expression was observed in both patients with
mild asthma (median value, 3.421) and those with moderate (me-
dian value, 7.63) asthma. The CCL17 expression correlated
weakly (r2 5 0.1493) but significantly (P 5 .0252) with sputum
eosinophilia (Fig 4) but not with neutrophil counts (r2 5 0.04).
When these analyses were performed on individual asthma
groups (mild asthma: r2 5 0.279, P 5 .063; moderate asthma:
r2 50.016, P 5 .7149) and healthy control subjects (r2 5 0.061,
P5 .1456) separately, none of these correlations were significant
nor was there a significant correlation when asthmatic patients
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FIG 1. Expression of biomarkers on MDMs stimulated with IL-4 or IL-13. A, Gene expression of CCL17 and
CLEC10A is expressed as fold induction compared with NT (not treated, mean6 SE, n5 11). B, Cell-surface
expression data are expressed as specific mean fluorescence intensity (SMFI; mean 6 SE, n 5 12). Data
were analyzed by using Friedman ANOVA and the Dunn multiple comparison test compared with NT.
*P < .05, **P < .01, and ***P < .001.
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FIG 2. Analysis of lung macrophage M2 marker expression by means of
flow cytometry. Expression of cell-surface CD163 on sputum and BAL
macrophages of healthy control subjects (HC), patients with mild asthma
(MA), and patients with moderate asthma (MO) is shown. Bars indicate me-
dian values, and numbers in parentheses indicate n. Data are expressed as
percentages of Live1CD451CD32HLA-DR1 cells and analyzed by using
Kruskal-Wallis ANOVA and the Dunn multiple comparison test. *P < .05
and ***P < .001.
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0.109,P5.1331), suggesting the correlation is probably ‘‘pulled’’
into significance because of the inclusion of low-CCL17-
expressing, low-eosinophil healthy control subjects. Although a
significant increase in CCL17 mRNA expression by BAL cells
was observed (P 5 .0449, Kruskal-Wallis test; Fig 4 and see
Fig E3 in this article’s Online Repository at www.jacionline.org),in contrast to the sputum data, this increase was only significant
when comparing patients with mild and moderate asthma by
using the Dunn post hoc test. There was a trend toward increased
expression of CLEC10AmRNA in both sputum and BAL macro-
phages from patients withmild but notmoderate asthma, although
this was not statistically significant (data not shown).Cytokine production by BAL fluid cells
To ascertain whether increased expression of CCL17 mRNA
in macrophages translated into increased release of CCL17
protein, freshly isolated BAL fluid cells (containing a median of
75% macrophages) were cultured for 24 hours, and supernatants
were analyzed for CCL17 by using the Luminex assay. The lack
of observed difference in CCL17 ex vivo release by BAL fluid
cells (see Fig E4 in this article’s Online Repository at www.
jacionline.org) suggested no correlation between the in vivo
gene expression and the ex vivo expression of CCL17. Addi-
tional cytokine measurements were also performed to assess
whether macrophages released a predominance of TH1 or TH2
cytokines. None of the TH2 (IL-4, IL-5, and IL-13) or TH1
(IFN-g, IL-2, and IL-12) cytokines were detected, whereas the
previously reported M1 (TNF, IL-6, and IL-8) and M2 (IL-10
and CCL22) biomarkers5 were released at similar levels in all
groups (see Fig E4).
Inhibition of CCL17 release by the PI3K inhibitor
LY294002 but not corticosteroids
The increased CCL17 mRNA expression observed in lung
macrophages from patients with moderate asthma taking inhaled
steroids suggested that the production of this chemokine might
not be fully responsive to corticosteroids. We therefore investi-
gated whether the ex vivo CCL17 release from macrophages
could be inhibited by steroid treatment. Initial experiments
TABLE II. Cell-surface and intracellular protein expression by macrophages from healthy control subjects, patients with mild asthma,
and patients with moderate asthma
Sputum BAL fluid
HC MA MO HC MA MO
Extracellular
HLA-DR (SMFI) 59,210
(44,120-75,520)
57,050
(40,780-76,880)
46,280
(42,470-63,470)
49,140
(34,100-56,390)
46,470
(36,650-57,300)
44,470
(30,760-61,870)
CD14 (SMFI) 1,920 (1,498-3,244) 1,729 (1,520-1,993) 1,932 (1,489-2,694) 1,260 (662.5-1,612) 1,328 (717.5-1,808) 1,049 (660-1,922)
CD206 (%) 62.4 (54.7-67.5) 47.7 (28.9-62.5) 56.8 (46.0-76.5) 57.9 (44.1-72.7) 51.6 (42.0-64.4) 57.5 (45.4-70.2)
CD301 (SMFI) 2,785 (1,439-5,921) 2,993 (1,674-3,852) 3,208 (2008-3,909) 2,727 (1,397-5,295) 3,314 (2,917-4,640) 2,540 (1,198-5,318)
Intracellular
TNF (SMFI) 3,781 (3,174-4,000) 4,464 (3,383-5,366) 3,867 (3379-4,831) 6,675 (5,232-8,380) 6,717 (5,172-8,141) 6,120 (5,473-7,148)
IL-10 (SMFI) 1,296 (1,005-1,735) 1,242 (1,001-1,900) 1,615 (814.5-2,472) 1,324 (722-2,229) 1,976 (1,700-2,179) 1,300 (920-2,014)
HLA-DR, CD14, CD301, TNF, and IL-10 are represented as specific mean fluorescence intensity (SMFI), and CD206 is shown as the percentage of cells staining positively. Data
are expressed as median values (interquartile ranges).
FIG 3. Sorting of lung macrophages for RT-PCR analysis. Sputum and BAL cells were stained according to
the method outlined. Live1CD451CD32HLA-DR1Lin 11 events were sorted into PBS with a FACSAria and
analyzed by using cytospin preparations (representative micrograph shown at 340 original magnification).
Data are expressed as a percentage of total cells, presented as means 6 SEs (n 5 6), and analyzed by using
the 1-tailed Wilcoxon signed-rank test. *P < .05.
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had no effect on the CCL17 release in response to 10 ng/mL IL-4
(Fig 5, A). We then studied whether inhibition of PI3K, the
enzyme suggested to be required for differentiation of monocytes
into M2 macrophages,23 could reduce CCL17 release. The pan-
PI3K inhibitor LY294002 caused a concentration-dependent inhi-
bition (median effective concentration 5 4.2 mM) that was
significant at 10 mM (Fig 5, A), with no significant lactate dehy-
drogenase (LDH) release (data not shown). Similar results were
obtained with 10 ng/mL IL-13 (data not shown). In contrast, the
specific PI3K-d inhibitor IC81174 had little effect on the amountof CCL17 released by IL-4–stimulated MDMs, except at the
highest concentration used (Fig 5, A), which caused an increase
in LDH release (data not shown). Similarly, the spontaneous re-
lease of CCL17 by BAL fluid cells from asthmatic patients
(n 5 13) was significantly inhibited by 10 mM LY294002 from
a mean of 14.82 to 7.49 pg/mL (Fig 5, B).DISCUSSION
In contrast to animal models of asthma, this study has
demonstrated only a partial M2 macrophage phenotype in
FIG 4. CCL17 mRNA levels (normalized to b2-microglobulin) and associa-
tion with sputum eosinophil counts. Bars indicatemedian values, and num-
bers in parentheses indicate n. Data were analyzed by using Kruskal-Wallis
ANOVA followed by the Dunn multiple comparison test. *P < .05 and **P <
.01. The association between CCL17 mRNA expression and the percentage
of sputum eosinophils was analyzed by using the Spearman rank correla-
tion test. Circles, Healthy control subjects; squares, asthmatic patients.
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FIG 5. A, Effects of fluticasone propionate and PI3K inhibitors on CCL17
release by IL-4–stimulated MDMs. Data are expressed as a percentage of
maximum IL-4 stimulation (mean6 SE, n5 5). Data were analyzed by using
Friedman ANOVA and the Dunn multiple comparison test. B, Effect of
LY294002 on spontaneous release of CCL17 from BAL cells compared to
cells not treated (NT) (n5 13). Data were analyzed by using the 1-tailed Wil-
coxon signed-rank test. *P < .05 and **P < .01.
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creased CCL17 mRNA expression and reduced CD163 cell-
surface expression when compared with that seen in healthy
subjects. Although blood monocytes did not express detectable
amounts of CCL17 mRNA (data not shown), increased expres-
sion was evident in lung macrophages, regardless of asthma se-
verity and treatment. The expression of CCL17 mRNA in
sputum correlated weakly with sputum eosinophilia, a hallmark
of asthma and a marker of TH2-type inflammation,
24 providing
a mechanism for increased recruitment of CCR41 cells (eosino-
phils and TH2 lymphocytes) for which CCL17 is a ligand. The
finding of persistently increased CCL17 mRNA levels in macro-
phages from both sputum and BAL of patients with moderate
asthma taking inhaled corticosteroids and the inability of cortico-
steroids to inhibit in vitro CCL17 release by M2 MDMs suggest
that CCL17 production is relatively corticosteroid insensitive. Fi-
nally, our study suggests that the production of CCL17 is regu-
lated by PI3K.
Studies of macrophages in asthma have reported on functional
readouts, such as suppression of T-cell proliferation and phago-
cytic function,25,26 cell-surface marker expression,27-29 and gene
expression.30-32 To our knowledge, this is the most comprehen-
sive investigation of M2 lung macrophage biomarkers in asth-
matic patients using combined cell-surface and gene expressionanalysis and measuring cytokine release. Two previous studies,
applying gene expression analysis32 and immunocytochemis-
try,29 respectively, showed no evidence for M2 macrophages in
asthmatic patients. Another study of M1/M2 macrophages in pa-
tients with chronic obstructive pulmonary disease (COPD) using
a combination of transcriptomic analysis, RT-PCR, and flow cy-
tometry33 showed that smoking was associated with increased
M2 phenotype gene expression, with further upregulation in
smokers with COPD and a reciprocal decrease in M1 phenotype
gene expression.33 However, the profile of differentially ex-
pressed M2 markers (eg, adenosine A3 receptor, matrix metallo-
proteinase [MMP] 2, and MMP7) was different from that seen in
our study, whereas CCL17 and CD163 were not differentially ex-
pressed in either healthy smokers or smokers with COPD.
Interpretation of the literature is complicated by differences in
the definition of M2 phenotypes based on the use of different
TABLE III. Differences in expression of IL-4/IL-13–induced M2 markers in different settings
Marker Murine MDM2* Human MDM2* M2 MDM model in current studyy Asthma macrophagesy
Gene expression
Arg1 [ No change No change No expression
Clec10a§ [ [ [ No change
Fizz1 [ No human homolog NT NT
Ym1 [ No human homolog NT NT
Cell-surface expression
CD23 [ [ NT NT
CD163 [38 Y22 Y Y
CD206 [ [ [ No change
MHCII/HLA-DR [ [ [ No change
Chemokine expression
CCL13k [ [ NT NT
CCL14 No murine homolog [ NT NT
CCL17 [ [ [ [
CCL18 No murine homolog [ NT NT
CCL22 [ [ [ No change
CCL24 [ [ NT NT
NT, Not tested.
*Information from Martinez et al,5 except where referenced differently.
Data from the current study.
Data from the pilot of this article obtained by using a slightly different culture model (see Fig E2 in this article’s Online Repository).
§Murine equivalent is MGL1.
kMurine homolog of CCL13 is CCL2.
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macrophage colony-stimulating factor,34 all of which produce
slightly different macrophage phenotypes. Atopic asthma is con-
sidered to involve TH2 cytokines,
2 and therefore in keeping with
the M2 phenotype described by Martinez et al,5 we have used
IL-4– and IL-13–stimulated MDMs as our M2 benchmark.
In the current study CCL17 and CD163 expression varied
considerably between the subjects studied, which is consistent
with the notion that asthma involves heterogeneous inflammatory
processes despite similar clinical phenotypes. Differences in
CCL17 expression were more pronounced in sputum than in BAL
fluid, which are sampled from the central airways and the distal
airways and alveoli, respectively,35 suggesting that the changes
reflect the proximal airways processes. Similarly, only the sputum
samples showed reduced levels of CD163.
The role of CCL17 in allergic inflammation has been the subject
of a number of studies showing increased release after allergen
exposure.12,13,36 Applying flow cytometry to induced sputum and
bronchial biopsy explants, we have previously shown an important
role for CCR4 and its ligand CCL17 in TH2 T-cell recruitment.
12
Stimulation of bronchial tissue explants by allergen induced
CCL17 release in steroid-naive asthmatic patients, but of more rel-
evance to the current study, spontaneous release was increased in
explants from patients with moderate asthma taking inhaled corti-
costeroids. Furthermore, the numbers of sputum and bloodCCR41
T cells were significantly increased in asthmatic patients taking
high-dose inhaled and oral corticosteroids. Taken together with
the current findings that CCL17 mRNA expression is persistently
high in corticosteroid-treated asthmatic patients and that in vitro
IL-4–induced CCL17 release byM2MDMs cannot be suppressed
by corticosteroids, this study adds to accumulating evidence that
CCL17 is an important chemokine in asthmatic patients, the
production of which is relatively corticosteroid insensitive.
Increased expression of CD163, a haptoglobin-hemoglobin
scavenger receptor,37 has been associated with the M2 phenotypein vitro.5,7,10,38 Although most studies showed a role for IL-4 and
IL-13 in driving this phenotype, Tiemessen et al7 showed it to de-
pend on IL-10 and not IL-4/IL-13. In contrast to the published
in vitro studies, we have found that CD163 expression is de-
creased in asthmatic patients. The finding that MDMs exposed
to IL-4 and IL-13 reduced CD163 expression suggests that TH2
cytokines might be responsible in asthmatic patients. In agree-
ment with our study, Van den Heuvel et al22 demonstrated that
IL-4 treatment decreases CD163 expression, although when
added to cells pretreated with glucocorticoids, it increases the ex-
pression. In contrast, in our study the reduced expression of
CD163 on sputum macrophages from asthmatic patients was
evident despite treatment with inhaled steroids, providing addi-
tional evidence of relative corticosteroid insensitivity. Thus our
observations are consistent with the notion that airway macro-
phages are relatively corticosteroid insensitive.39
Having found the macrophages to be insensitive to corticoste-
roids, we sought an alternative therapy targeting PI3K, the
enzyme postulated to be required for the differentiation of M2
macrophages.23 For this purpose, LY294002 was selected on
the basis of its relative selectivity for PI3K. At a concentration
of 10 mM, this compound was effective at inhibiting CCL17 re-
lease from both cultured BAL fluid cells and IL-4–stimulated
MDMs. Although this suggests the involvement of PI3K, it is rec-
ognized that at concentrations of greater than 10 mM, LY294002
inhibits other kinases.40 Previous studies have suggested that in-
hibiting the PI3K-d isoform is effective at reducing airway in-
flammation and hyperresponsiveness in murine models of
asthma.41 Furthermore, inhibition of PI3K-dwith theophylline re-
verses the steroid insensitivity of macrophages from patients with
COPD.42 However, the specific PI3K-d inhibitor IC87114 had lit-
tle effect on IL-4–induced CCL17 release from MDMs, suggest-
ing that, in contrast to the murine model,23 an isoform other than
PI3K-d is involved in IL-4–induced CCL17 production in human
macrophages. In summary, this study suggests involvement of the
J ALLERGY CLIN IMMUNOL
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quire more specific inhibition using such tools as inhibitory
RNAs.
This study raises a number of questions and opportunities for
further research. Previous studies8 have shown that CLEC10A
mRNA expression is increased on M2 MDMs, and there have
been reports of increases onmacrophages in patientswith a number
of diseases.43-45 However, to our knowledge, there have been no
studies of both mRNA and protein expression. In our study there
was a trend toward increased CLEC10A mRNA but not CD301
(the protein marker of CLEC10A) expression in macrophages of
asthmatic patients. Future studies will need to look for internalized
or intracellular CD301 expression. The difference in CCL17
mRNA expressionwas greater in sputum than in BAL, and the rea-
sons for that are unclear. This discrepancy could, at least in part, ac-
count for the lack of difference in CCL17 protein release by BAL
fluid cells ex vivo. Other cell types, although they constituted, on
average, 30% of total BAL fluid cells, might have bound some of
the cytokines/chemokines released in culture (eg, CCL17 by
CCR41 cells). Furthermore, contact with plastic might have al-
tered the BALmacrophage phenotype.46 Similarly, the in vivo con-
ditions required for the phenotype to be detected might not be
sustained ex vivo. However, it is unlikely that either of thesewould
have offset any intrinsic differences between macrophages from
patients and healthy subjects. When studying macrophage func-
tion, stimuli are often used, but we chose not to expose the BAL
fluid cells to any exogenous stimuli, such as LPS, because this
could skew responses toward anM1profile.5 Finally, thebiomarker
panel in this study was limited to biomarkers published at the time
the studywas conceived; further studies should focus on additional
M2 biomarkers, such as MMP2 and MMP7.33
The driver of the macrophage phenotype in asthmatic patients
remains unclear. It is possible that IL-4 and IL-13 do provoke this
phenotype but that our MDM model does not encapsulate the
full complexity of macrophage interactions within the lung
environment. IL-4/IL-13 and activation of signal transducer and
activator of transcription 6 might not be involved in the devel-
opment of the CCL17-producing macrophages. The promoter for
CCL17 also contains nuclear factor kB (NF-kB) motifs,47,48 and
the archetypal NF-kB activator, TNF, induces expression of
CCL17 mRNA in human bronchial epithelial cells.49 Infection
of murine lung epithelium with respiratory syncytial virus
activates the NF-kB pathway to produce CCL1750 and switches
macrophages to a M2 phenotype.51 Moreover, the house dust
mite allergenDermatophagoides pteronyssinus (Der p 1), also in-
duces CCL17 mRNA and protein expression in cultured primary
bronchial epithelial cells through an epithelial growth factor re-
ceptor/NF-kB–dependent pathway.16 Because both respiratory
syncytial virus and Der p 1 are implicated in asthma,52,53 these
agents may activate macrophages through NF-kB–dependent
pathways to produce CCL17 in a steroid-independent manner.
This study has involved a mix of eosinophilic and non-
eosinophilic asthma. The increasing recognition that phenotypes
based on eosinophilic and neutrophilic inflammation are different
clinically and in respect of response to corticosteroids will require
further study of the identified biomarkers in these phenotypes.
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Key messages
d Lung macrophages in asthmatic patients do not express
biomarkers associated with the alternative M2 phenotype
reported in studies of MDMs and animal models.
d Lung macrophages of asthmatic patients express more
CCL17 and less CD163, and the former is associated, al-
though weakly, with sputum eosinophilia and cannot be
suppressed by corticosteroids but can be attenuated by
PI3K inhibition.
d Macrophage expression of CCL17 may contribute to the
airway inflammation observed in asthmatic patients
through recruitment of cells expressing CCR4, the cell-
surface receptor for CCL17.
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Monocyte isolation and differentiation into M2
macrophages
PBMCs from healthy control subjects and asthmatic patients were isolated
from heparinized blood by means of centrifugation on Lymphoprep (Axis-
Shield, Oslo, Norway). Monocytes were then isolated from the PBMCs by
using CD141microbeads (Miltenyi Biotec, Bisley, United Kingdom), accord-
ing to the manufacturer’s instructions. Isolated monocytes were resuspended
in RPMI supplemented with 10% heat-inactivated FBS, 2 mg/ml L-glutamine,
0.05 U/mL penicillin, 50 mg/mL streptomycin, and 0.5 mg/mL amphotericin
B (all from Invitrogen).
In preliminary experiments leading to this work, monocytes were cultured
in 20 ng/mL IFN-g or IL-4 (both from R&D Systems, Abingdon, United
Kingdom). After 72 hours, cells were harvested for flow cytometry and gene
expression analysis (Fig E2).
For the main body of work, monocytes were differentiated into macro-
phages over 12 days in the presence of 2 ng/mL GM-CSF (R&D Systems),
according to the method of Tudhope et al.E1 MDMs were then washed exten-
sively with basal RPMI before addition of RPMI supplemented as abovewith-
out GM-CSF followed by addition of IL-4 or IL-13 (10 ng/mL, both from
R&D Systems) for 24 hours to polarize them toward a M2 phenotype. For
flow cytometric analysis, MDMs generated were removed from culture plates
by using a nonenzymatic cell dissociation solution (Sigma, Poole, United
Kingdom) before resuspending in FACS buffer (PBS, 0.5% wt/vol BSA,
and 2 mM EDTA) containing 2 mg/mL human IgG (Sigma). For RNA isola-
tion, Stratagene lysis buffer was added directly to the plates after removal of
supernatants. Lysis buffer was then removed to Eppendorf tubes before stor-
age at 2808C. Although MDMs were generated from a mixture of asthmatic
patients (n5 6) and healthy control subjects (n5 5), no significant difference
in IL-4–induced expression of CCL17 and CLEC10A steady-state mRNAwas
observed between these 2 groups (data not shown).
Flow cytometric analysis of MDMs
For phenotypic characterization of cytokine-stimulated MDMs, cells
resuspended in FACS buffer were stained with mixtures of APC-Cy7–labeled
anti–HLA-DR (BD Biosciences), PerCP-Cy5.5–labeled anti-CD14 (BD Bio-
sciences), andAF647-labeled anti-CD301 (CambridgeBioscience,Cambridge,
United Kingdom); mixtures of APC-labeled anti-CD206 (BD Biosciences),
PerCP-Cy5.5-labeled anti-CD163 (Cambridge Bioscience), and fluorescein
isothiocyanate–labeled anti-CD36 (BD Biosciences); or appropriate isotype
controls for 30 minutes on ice. Analysis was performed on a 9-color FACSAria
cell sorter (BD Biosciences) with FACSDiva Software (version 5.0.3).
Collection of lung cell samples
Sputum induction and solubilization were performed as previously
described.E2 Fiberoptic bronchoscopy was carried out in accordance with
the recommendations of the American Thoracic Society.E3 One hundred
twenty milliliters of normal saline was instilled into the right upper lobe and
recovered by means of aspiration. Cell aliquots were immediately resus-
pended in FACS buffer containing 2 mg/mL human IgG or cultured in AIM
V media supplemented with 0.05 U/mL penicillin, 50 mg/mL streptomycin,
0.5 mg/mL amphotericin B, 1 mmol/L sodium pyruvate and 0.004% (vol/
vol) 2-mercaptoethanol (all from Invitrogen) at a concentration of 1 3 106
cells/mL for 24 hours.
Flow cytometry of lung macrophage biomarkers
Phenotypic characterization of lung macrophages was performed by using
flow cytometry with a 9-color FACSAria cell sorter (BD Biosciences) and
FACSDiva Software (version 5.0.3). Sputum and BAL fluid cells were
incubated in reagents from the Live/Dead Violet Viability/Vitality kit and
themacrophage detection cocktail, consisting of anti-humanCD45 PE-AF610
(Invitrogen), anti-human CD3 PE-Cy7 (BD Biosciences), and anti-human
HLA-DR APC-Cy7. By using this protocol, CD451CD32HLA-DR1 cells
were shown to be composed of greater than 90% pure macrophages, as shown
by using cytologic analysis of sorted cells (Fig E1).Separate aliquots were additionally incubated in a cocktail of antibodies
againstM2 surfacemarkers (anti-CD206APC and anti-CD14 PerCP-Cy5.5 or
anti-CD301 AF647 and anti-CD163 PerCP-Cy5.5) or isotype control anti-
bodies. CD206 and CD163 are expressed as percentages of cells because in
most cases there was a clear positive and negative population, whereas CD14
andCD301 are represented as the specificmean fluorescence intensity because
the entire selected population stained positive compared with the isotype
control.
For intracellular staining, separate aliquots of cells that had been incubated
in the macrophage identification cocktail were first washed with FACS buffer
and then incubated in Cytofix/Cytoperm (BD). These cells were further
washed in 13 Perm/Wash and incubated with anti-human CD68 PE (BD),
anti-human TNF APC (eBioscience, San Diego, Calif), anti–IL-10 AF647
(BioLegend, San Diego, Calif), or isotype control. Intracellular cytokine
staining is represented as the specific mean fluorescence intensity because the
entire selected population stained positive compared with the isotype control.
The 90% purity of macrophages obtained by using the above method of
selection was considered insufficient for gene expression analysis because any
small contamination with other cell types could be amplified during PCR.
Therefore we added the Lin 1 antibody cocktail (BD Biosciences) to the
macrophage detection protocol, which made it possible to exclude dendritic
cells from the analysis. Cells sorted in this way (CD451CD32Lin1HLA-
DR1, Fig 3) from both sputum and BAL fluid were, on average, 98% pure
macrophages, as ascertained based on histochemical and morphologic analy-
sis of cytospin preparations. When theses slides were stained for CD68 by us-
ing immunocytochemistry, a slightly lower percentage of the sorted cells
(91%) were CD681, with some cells that were morphologically clearly of
the macrophage phenotype not staining positively. Up to 100,000 events
were sorted into RNA lysis buffer and stored at2808C before RNA extraction
and RT-PCR.
RNA isolation and RT-PCR
RNAwas isolatedwith aStratageneMicroprepKit.Reverse transcriptionwas
carried out with a PrimerDesign nanoScript Reverse Transcriptase kit. PCR
amplificationswere performedonaBioRad iCycler by usingPrecision 2XqPCR
Mastermix with or without SYBR Green and the following primers (all
from PrimerDesign): Indoleamine 2,3-dioxygenase (INDO), forward 59- TGT
GGC AGCAAC TAT TATAAG ATG -39 and reverse 59- CAC TTC TTC ATC
AATATG GTA CTC TT -39; CCR7, forward 59- AAG CCT GGT TCC TCC
CTA TC -39 and reverse 59- ATG GTC TTG AGC CTC TTG AAA TA -39;
CXCL10, forward 59- CAGAGGAACCTCCAGTCTCAG -39 and reverse 59-
GGT ACT CCT TGA ATG CCA CTT A -39; ARG1, forward 59- ATCCC-
TAATGACAGTCCCTTTC -39 and reverse 59- GCTGATTCTTCCGTTCTT
CTTG -39; CCL17, forward 59- GAGCCATTCCCCTTAGAAAGC -39 and
reverse 59- GCATTCTTCACTCTCTTGTTGTT -39; CCL22 forward 59- AAT
TTG CCC AGATTC ACC TTT C -39 and reverse 59- AATAAG CCA AGA
CCA CAC CAT T -39; and CLEC10A forward 59- AGCTGAGGTG-
GAGGGTTTC -39 and reverse 59- GTGTGCCTTCTGCGTAGTG-39.
Gene expression was normalized to the relative concentration of the
housekeeping gene b2-microglobulin (designed and validated by PrimerDe-
sign), as determined in a separate PCR.
Cell (MDMs and BAL) culture and supernatant
analyses
MDMs generated from monocytes obtained from 5 subjects were cultured
in RPMI-1640 (110% FBS) for 24 hours and stimulated with 10 ng/mL IL-4
in the presence or absence of a range of concentrations of fluticasone
propionate (Sigma) or PI3K inhibitors (Calbiochem, Feltham, United King-
dom). Cell supernatants were harvested, and CCL17 concentrations were
measured by using ELISA, according to the manufacturer’s instructions
(R&D Systems). LDH release was measured with the CytoTox 96 Non-
Radioactivity Cytotoxicity Assay (Promega, Southampton, United Kingdom),
according to the manufacturer’s instructions.
Supernatants from unstimulated BAL cells cultured in AIM V medium for
24 hours, comprising median 75% macrophages, 6.4% neutrophils, 2.5%
eosinophils, 1% lymphocytes, and 15% epithelial cells, were analyzed by
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multiple cytokines (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13,
TNF-a, IFN-g, and CCL22), according to the manufacturer’s instructions.
Briefly, recombinant cytokines for standard curve generation were
purchased from R&D Systems. Capture and detection antibodies were
from R&D Systems (TNF-a, macrophage-derived chemokine, and thymus
and activation-regulated chemokine), BD Pharmingen (Oxford, United
Kingdom) (IL-2, IL-4, and IL-13 capture antibodies and IL-5, IL-10, IL-
12p70, and IL-13 detection antibodies), Endogen (Loughborough, United
Kingdom) (IFN-g, IL-6, IL-8, IL-10, and IL-12p70 capture antibodies
and IFN-g, IL-4, IL-6, IL-8, and IL-12p70 detection antibodies), and
GlaxoSmithKline (Stevenage, United Kingdom; IL-5 capture antibody).
Briefly, 50 mL of standards or samples was placed on a 96-well filter plate
(Millipore, Watford, United Kingdom) prewetted with 50 mL of assay buffer
(PBS, 1% BSA, and 0.025% Triton-X100). Fifty microliters of appropriate
antibody-conjugated xMAP Carboxylated Microspheres (Applied Cytometry
Systems, Sheffield, United Kingdom) was added to each well (13 105 micro-
spheres/mL for each conjugated microsphere set), and the plate was covered
and incubated at 48C overnight. After 2 washes with wash buffer (PBS and
0.05% Tween-20), 50 mL of a cocktail of appropriate detection antibodies
(500 ng/mL for each antibody) was added to each well and incubated on a
shaker at 700 rpm for 1 hour at room temperature. After 2 further washes,
50 mL of streptavidin-PE (1 mg/mL in assay buffer, BD Biosciences) was
incubated on a shaker for 30 minutes at room temperature at 750 rpm. The
plate was then washed twice, and 120 mL of sheath fluid was added to
each well before reading on a Luminex xMAP100 machine (Bio-Rad).
Results were analyzed with STarStation 2.0 software (Applied Cytometry
Systems).REFERENCES
E1. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes
PJ, et al. Different mitogen-activated protein kinase-dependent cytokine responses
in cells of the monocyte lineage. J Pharmacol Exp Ther 2008;324:306-12.
E2. Vijayanand P, Seumois G, Pickard C, Powell RM, Angco G, Sammut D, et al.
Invariant natural killer T cells in asthma and chronic obstructive pulmonary
disease. N Engl J Med 2007;356:1410-22.RESULTS
Identification of lung macrophages using flow
cytometry
Initial identification of macrophages used the specific macro-
phage marker CD68. However, CD68 is an intracellular marker
that can only be detected after fixation and permeabilization of
cells. To sort live cells for gene expression studies, surfacemarkers
were required to identify macrophages. CD681 macrophages
were therefore identified as being CD451CD32HLA-DR1
events (Fig E1, A). To corroborate that the combination of
CD451CD32HLA-DR1 cells was suitable for identifying macro-
phages, this cocktail of antibodies was combined with a Live/Dead
stain (Invitrogen), and Live1CD451CD32HLA-DR1 events were
sorted and centrifuged onto cytospin slides. Histochemical and
morphologic analysis of the subsequent slides revealed that cells
sorted by using this method were 90% macrophages (sputum, 6
5.4% [n 5 3], BAL fluid, 6 4.2% [n 5 5]) compared with 26%
macrophages in presorted sputum (6 7.5% [n5 3]) and 83%mac-
rophages in presorted BAL fluid (6 3.8% [n 5 5], Fig E1, B).
In previous studies alveolar macrophages have been identified
by using flow cytometry on the basis of high autofluorescence in
the FL1 and FL2 channels (corresponding to fluorescein isothi-
ocyanate and PE, respectively) when excited by a 488-nm
laser,E4,E5 and this was a particular problem with early single-
laser, 2-color flow cytometers. Some investigators have tried to
mitigate the effects of autofluorescence by quenching with crystal
violet,E6 whereas others used this autofluorescence to success-
fully sort pure populations of macrophages.E7 More recently,
analysis has progressed because of the introduction of different
dyes that emit peak fluorescence outside of the autofluorescence
window (eg, PerCP-Cy5 and APC) and flow cytometers that in-
corporate more than 1 laser.E8,E9 We are fortunate to have a
3-laser FACSAria in our division, which allows simultaneousdetection of 9 different fluorochromes. Furthermore, this instru-
ment incorporates fiberoptic pathways for collection of emitted
light, which, in combination with the band-pass filters in front
of the detectors, allows better discrimination of selected wave-
lengths. In our study we also used the BD standard automatic
compensation protocol to reduce the amount of observed auto-
fluorescence to a minimum. Thus when we analyzed BAL fluid
cells using flow cytometry, themedian percentage of Live1 events
that exhibited FL1:FL2 autofluorescence was 3.5%, whereas the
median percentage of macrophages in those samples was 79.4%
(Fig E1, C), demonstrating that autofluorescence of the alveolar
macrophages did not interfere with our investigations.
Identification of CCL17 and CLEC10A mRNA
expression in BAL fluid macrophages from airways
of asthmatic patients
To ascertain a signature associated with an M1 or M2 pheno-
type, we initially stimulated CD141 isolated monocytes in the
presence of IFN-g or IL-4 (both at 20 ng/mL), respectively, for
3 days and analyzed the expression of surface receptors and genes
(Fig E2) previously identified as markers of these phenotypes
(M1: CXCL10, CCR7, and INDO; M2: CLEC10A, CCL17, and
CCL22). As previously described, IFN-g causes increases in sur-
face expression of CD14 but decreases in expression of CD206,
whereas IL-4 increases CD206 expression but decreases CD14
expression. At the RNA level, IL-4 caused monocytes to express
increased steady-state levels of CLEC10A, CCL17, and CCL22,
whereas IFN-g only significantly increased expression of
CXCL10.
To validate this MDM-derived gene signature in lung macro-
phages, we analyzed the expression of this same panel of genes in
macrophages sorted from BAL fluid using a separate cohort of 4
asthmatic volunteers and 4 healthy control subjects. As in the case
of MDMs, this analysis also showed undetectable expression of
INDO. Although the other genes tested first in MDMs were
detectable, CXCL10, CCR7, and CCL22 were not different
between macrophages from asthmatic and healthy subjects, and
only CLEC10A and CCL17 seemed to be clearly differentially
expressed between asthmatic patients and healthy subjects in this
pilot cohort of volunteers (Fig E3). Therefore analysis of these 2
genes was taken forward on more subjects.
Ex vivo release of chemokines and cytokines by BAL
cells
To ascertain whether increased expression of CCL17 mRNA
from lung macrophages was translated into increased release of
this chemokine, freshly isolated BAL cells were incubated for 24
hours, and supernatants were harvested to analyze CCL17 release
by using the Luminex assay; additional cytokines were also
assayed. Only TNF, IL-6, IL-8, IL-10, CCL17, and CCL22 from
the Luminex panel were released at detectable levels, with no
significant difference between subject groups in the amounts
released (Fig E4).
E3. Djukanovic R, Wilson JW, Lai CK, Holgate ST, Howarth PH. The safety aspects
of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in
asthma. Am Rev Respir Dis 1991;143:772-7.
E4. Skold CM, Hed J, Eklund A. Smoking cessation rapidly reduces cell recovery in
bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains
high. Chest 1992;101:989-95.
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macrophage phenotype in chronic obstructive pulmonary disease patients,
smokers and non-smokers. Clin Exp Immunol 2006;145:428-37.
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rophages by flow cytometry. Am J Physiol Lung Cell Mol Physiol 1997;272:
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ysis of alveolar macrophages and monocytes in allergic airway inflammation. I.
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FIG E1. Analysis of lung macrophage M2 marker expression by means of flow cytometry. A, Cell
pellets from sputum and BAL were incubated with Aqua Dead Dye (Invitrogen) and the antibodies
PE-AF610–labeled anti-CD45, PE-Cy7–labeled anti-CD3, and APC-Cy7–labeled anti–HLA-DR or appropriate
isotype controls. After fixation and permeabilization, cells were incubated with PE-labeled anti-CD68
or an appropriate isotype control. Backgating of CD451CD32CD681 events demonstrates that all these
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cells express high levels of HLA-DR. Plots are representative of 10 independent sputum samples.
B, Live1CD451CD32HLA-DR1 events were sorted into PBS by using a FACSAria, and the selected cells
were loaded onto a cytospin and stained with Diff-Quick. Cells were counted, and data are expressed as
a percentage of nonsquamous cells and presented as means 6 SEs (sputum, n 5 3; BAL, n 5 5). Data
were further analyzed by using the 1-tailed Mann-Whitney U test. *P < .05 compared with the presort sam-
ple. C, Representative scatter plot showing low fluorescein isothiocyanate (FITC)/PE autofluorescence of
Live1 events from BAL samples.
=
NT IFN IL-4
0
300
600
900
C
D
1
4
 
(
S
M
F
I
)
NT IFN IL-4
0
100
200
300
C
D
2
0
6
 
(
S
M
F
I
)
NT IFN IL-4
0
2
4
6
C
X
C
L
1
0
/
β2
M
NT IFN IL-4
0
25
50
75
C
C
R
7
/
β2
M
NT IFN IL-4
0
300
600
900
C
C
L
1
7
/
β2
M
NT IFN IL-4
0
1000
2000
3000
C
C
L
2
2
/
β2
M
NT IFN IL-4
0.0
2.5
5.0
7.5
C
L
E
C
1
0
/
β2
M
A
B
FIG E2. Humanmonocytes respond to TH2 cytokines. A,Monocytes were stimulated with IL-4 (20 ng/mL) for
24 hours and analyzed for cell-surface expression of CD14 and CD206 by means of flow cytometry. Data are
expressed as mean fluorescence intensity corrected for isotype control staining (SMFI) and presented as
means 6 SEs (n 5 4). B, Gene expression of M1 or M2 biomarkers was analyzed by means of RT-PCR.
Data were normalized to b2-microglobulin (b2M) and are expressed as means 6 SEs (n 5 4). NT, Not
treated.
J ALLERGY CLIN IMMUNOL
VOLUME 130, NUMBER 6
STAPLES ET AL 1412.e5
Healthy Asthma
0
1
2
3
4
C
X
C
L
1
0
/
β2
M
Healthy Asthma
0
2
4
6
C
C
R
7
/
β2
M
Healthy Asthma
0
1
2
C
C
L
1
7
/
β2
M
Healthy Asthma
0
1
2
3
C
C
L
2
2
/
β 2
M
Healthy Asthma
0
1
2
3
4
C
L
E
C
/
β2
M
FIG E3. Preliminary analysis of BAL macrophage gene expression. Live1CD451CD32HLA-DR1Lin 11 events
from BAL of 4 healthy control subjects and 4 asthmatic patients were sorted into lysis buffer, and RNA was
extracted and reverse transcribed. Steady-state levels of gene expression weremeasured by using real-time
PCR and normalized to b2-microglobulin (b2M). Bars indicate median expression relative to b2M.
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FIG E4. Ex vivo release of cytokines by BAL cells from healthy control subjects (HC), patients with mild
asthma (MA), or patients with moderate asthma (MO). Spontaneous release of cytokines into supernatants
after 24 hours in cell culture was assessed by using the Luminex assay. Bars indicate median values, and
data were analyzed with a Kruskal-Wallis ANOVA followed by the Dunn multiple comparison test.
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